Calculation of CER coefficients for different severity levels of bronchial asthma_
| Severity | Treatment tactics | The cost of the course, USD (tenge) | Effectiveness, % | CER |
|---|---|---|---|---|
| Mild | Scheme 1 | USD 5.4 (2380 tenge) | 70 | 0.077 (34) |
| Scheme 2 | USD 10.8 (4760 tenge) | 63 | 0.171 (75.5) | |
| Moderate | Scheme 1 | USD 11.17 (4920 tenge) | 40 | 0.27 (123) |
| Scheme 2 | USD 19.61 (8640 tenge) | 56 | 0.35 (154.2) | |
| Severe | Scheme 1 | USD 25.3 (11150 tenge) | 50 | 0.506 (223) |
| Scheme 2 | USD 47.88 (21100 tenge) | 60 | 0.798 (351.6) |
Distribution of patients according to severity, age_
| Degree of severity | Age | Number of people |
|---|---|---|
| Mild | From 6 to 8 years old | 10 |
| From 9 to 12 years old | 8 | |
| Medium | From 6 to 8 years old | 12 |
| From 9 to 12 years old | 9 | |
| Severe | From 6 to 8 years old | 10 |
| From 9 to 12 years old | 5 |
Treatment regimens depending on the stage, age_
| The stage of bronchial asthma | Age | Medication | Cost USD (tenge) |
|---|---|---|---|
| The mild stage | 6–8 years | Berodual inhalation solution 20 ml 1 fl | USD 5.4 (2380 tenge) |
| 9–12 years | Berodual inhalation solution 20 ml 2 fl | USD 10.8 (4760 tenge) | |
| The medium stage | 6–8 years | Flixotide 50 mcg 120 doses 1 fl + Salbutamol 100 mcg 200 doses 1 fl | USD 11.17 (4920 tenge) |
| 9–12 years | Flixotide 50 mcg 120 doses 2 fl + Salbutamol 100 mcg 200 doses 1 fl | USD 19.61 (8640 tenge) | |
| The severe stage | 6–8 years | Symbicort 80/4.5 mcg 120 doses of 1 fl. + Salbutamol 100 mcg 200 doses of 1 fl. | USD 25.3 (11150 tenge) |
| 9–12 years | Symbicort 80/4.5 mcg 120 doses 2 fl. + Salbutamol 100 mcg 200 doses of 1 fl. | USD 47.88 (21100 tenge) |
The number of exacerbations, according to the treatment regimens in each group_
| The stage of bronchial asthma | Age group | Number of patients | Treatment regimen | The frequency of exacerbations per year | Percentage ratio |
|---|---|---|---|---|---|
| The mild stage | 6–8 years old | 10 | Scheme 1 | 3 | 30% |
| 9–12 years old | 8 | Scheme 2 | 3 | 37% | |
| The medium stage | 6–8 years old | 12 | Scheme 1 | 6 | 60% |
| 9–12 years old | 9 | Scheme 2 | 4 | 44% | |
| The severe stage | 6–8 years old | 10 | Scheme 1 | 5 | 50% |
| 9–12 years old | 5 | Scheme 2 | 2 | 40% |